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Bouvardain is an antitumor drug that inhibits protein synthesis in intact eukaryotic cells and cell-free 
systems. Our present studies have shown that bouvardin acts at the level of the 80 S ribosome in a site 
somehow involved with the interaction of EFl and EF2. Indeed bouvardin inhibits EFI-dependent bind- 
ing of aminoacyl-tRNA and EF2-dependent translocation of peptidyl-tRNA but does not affect the non- 
enzymic translocation since this reaction does not require EF2. The site of the 80 S ribosome involved in 
the interaction with bouvardin appears to be independent from the cycloheximide and the cryptopleurine 
binding sites since yeast mutants resistant o cycloheximide or cryptopleurine are sensitive to bouvardin. 
Bouvardin Protein synthesis Translocation 
1. INTRODUCTION 
Bouvardin is a cyclic hexapeptide (fig.]) which 
is isolated from Bouvardia ternifolia (Rubiaceae). 
This plant was used by ancient Mexican Indians as 
a general medicine and it is still used in Mexico as 
a drug against disentery and other diseases [l]. 
Bouvardin shows high antitumor activity in the P5 
and Bl systems ]I] as well as against P388 lympho- 
cytic leukemia and B16 melanoma 121. The effects 
of bouvardin on macromolecule synthesis by P388 
tumor cell suspensions indicate that protein syn- 
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Fig.1. Chemical structure of bouvardin. 
High salt washed ribosomes and polyribosomes 
from yeast, partially purified yeast supernatant 
fraction containing elongation factors EF- 1 and 
EF-2, [3H]Phe-tRNA, rabbit reticulocyte ribo- 
somes and purified elongation factors EF-1 and 
EF-2 from reticulocytes were prepared as in [4,5]. 
The assay systems for poly(U)- and endogenous 
mRNA-directed polypeptide synthesis, enzymic 
binding of [3H]Phe-tRNA to reticulocyte ribo- 
somes, enzymic and non-enzymic translocation by 
yeast polyribosomes and the EF-2- and GTP-de- 
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thesis is inhibited preferentially to RNA and DNA 
synthesis [2]. These findings are interesting since 
other cyclic oligopeptides (gramicidins, tyrocidins, 
polymixins and octapeptins) are known to act in a 
completely different way; i.e., by affecting the 
structure of the cell membrane and producing lysis 
of bacterial and animal cells [3]. We have studied 
the mode of action of bouvardin on several steps 
of protein synthesis using resolved model systems 
from both yeast and reticulocytes. It has been con- 
cluded that bouvardin blocks polypeptide chain 
elongation by inhibiting both the GTP- and EF-2- 
dependent ranslocation of peptidyl-tRNA and the 
enzymic binding of aminoacyl-tRNA to 80 S ribo- 
somes. 
2. MATERIALS AND METHODS 
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pendent translocation of N-Ac13H]Phe-tRNA were 
described in (4,6,7]. Bouvardin was a gift of Dr M. 
Chitnis. Radioactive compounds were obtained 
from Amersham International (Bucks). 
3. RESULTS AND DISCUSSION 
Bouvardin clearly inhibits protein synthesis in 
yeast cell-free systems. Thus, poly(U)-directed 
polyphenylalanine synthesis and endogenous 
mRNA-programmed polypeptide synthesis by 
these extracts were inhibited by 50% at 4 x 10 -(j M 
and >90% at 4X lOA M bouvardin (tig.2). 
The inhibition of polypeptide chain elongation 
could be explained by the blocking of aminoacyla- 
tion of tRNA. However, results obtained by our- 
selves (not shown) and others [2] indicate that the 
aminoacylation reaction takes place in the pres- 
ence of bouvardin. Therefore, we have studied the 
effects of the cyclic hexapeptide on several model 
reactions of the elongation cycle. Neither peptidyl- 
[3H]puromycin nor N-acetyl-[3H]leucylpuromycin 
synthesis was affected by up to 4 x 10-X M 
bouvardin as measured by the reaction of yeast 
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Fig.2. The effect of bouvardin on poly(U)-directed poly- 
phenylalanine and endogenous mRNA-directed poly- 
peptide synthesis by yeast ribosomal preparations. The 
reactions took place over 20 min. Other conditions were 
as in (4). Incorporation in the controls in the absence of 
bouvardin was 180 and 15 pmol [jH]phenylalanine for 
poly(U)- (o) or endogenous (0) mRNA-directed poly- 
Fig.3. The effect of bouvardin on a number of model 
reactions of the elongation cycle of protein synthesis. 
Reactions were carried out as in Materials and Methods. 
(o) Enzymic translocation by yeast polyribosomes. 0.6 
and 1.3 pmol peptidyl-[3H]puromycin were synthesized 
in the controls in the absence and in the presence of 
added yeast supernatant factors, respectively. (m) Elon- 
gation factor EF-2- and GTP-dependent translocation 
of N-acetyl-[3H]phenylalanine_tRNA by reticulocyte 
ribosomes; 1.1 pmol N-acetyl-[3H]phenylalanyl-tRNA 
was translocated in the control in the absence of bouvar- 
din. (e) Non-enzymic translocation by yeast polyribo- 
somes; 11 pmol peptidyl-[3H]puromycin were syn- 
thesized in the control in the absence of bouvardin. (A) 
Enzymic binding of [sHIPhe-tRNA; 2.1 pmol ]3H]Phe- 
peptide synthesis. tRNA were bound in the absence of drug. 
polyribosomes with [3H]puromycin or by the ‘frag- 
ment reaction’, respectively (not shown). It was 
concluded that the peptide bond formation step 
was not affected by bouvardin. 
When the reaction of [3H]puromycin with yeast 
polyribosomes was carried out in the presence of 
GTP and supernatant factors bouvardin did inhib- 
it the formation of peptidyl-[3H]puromycin (tig.3). 
Under these conditions translocation of peptidyl- 
tRNA takes place and consequently the inhibition 
of the reaction may be due to the action of bouvar- 
din on translocation. The interaction of bouvardin 
with the translocation step is also sugested by the 
reversal of the inhibition of polyphenylalanine 
synthesis by increasing amounts of elongation fac- 
tor EF-2 in a reticulocyte cell-free system (fig.4). 
However, bouvardin does not affect the non-en- 
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Figd. Effects of different amounts of elongation factor 
EF-2 on the inhibition of polyphenylalanine synthesis 
by bouvardin. Polyphenylalanine synthesis was per- 
formed as in [7]. Incorporation in the controls in the 
absence of drug was: 0.5, 2.1, 2.7 and 3.0 pmol 
[sH]phenylalanine for 0.5, 1.5, 2 and 3 pg elongation 
factor EF-2 added. When required, bouvardin was 
present at: (o) 4 x 10 -5 M or (0) 4 x 10 -4 M. 
zymic translocation [6] that takes place in the pres- 
ence of high [K+] and in the absence of elongation 
factor EF-2 and GTP (tig.2). An analogous situa- 
tion has been found with several inhibitors of the 
enzymic translocation that bind to the small 
ribosomal subunit (cryptopleurine, emetine, tu- 
bulosine and hygromycin B) [8]. In contrast, 
cycloheximide and pederine that bind to the 60 S 
ribosomal subunit, block both the enzymic and 
non-enzymic reactions. Thus, bouvardin may act 
on the 40 S subunit, although there are no direct 
experimental bases for this suggestion. 
The EF-1 and GTP-dependent binding of 
[3H]phenylalanyl-tRNA to 80 S ribosomes was 
also inhibited by bouvardin, although to a lower 
extent than the inhibition of translocation (fig.2). 
This is the first instance that an antibiotic inhibits 
both aminoacyl-tRNA binding and translocation 
in a eukaryotic system. In prokaryotic systems, 
drugs of the thiostrepton group inhibited both re- 
actions, evidence for the existence of overlapping 
binding sites for elongation factors G and Tu on 
the ribosome [9]. Analogously, our results with 
bouvardin also suggest that overlapping sites for 
EF-I and EF-2 may exist in the eukaryotic ribo- 
some. In support of this suggestion is the fact that 
aminoacyl-tRNA does not bind to GDP l 80 S 
ribosome l fusidic acid l EF-2 complexes [lo]. 
Ribosomes from yeast strains resistant to 
cycloheximide or cryptopleurine are sensitive to 
bouvardin (unpublished). This result suggests that 
the interaction of bouvardin with the 80 S ribo- 
some defines a new ribosomal binding site. The 
high content of tyrosine in bouvardin should allow 
one to label the molecule with 1251. If the resulting 
derivatives were active, they could prove useful in 
the study of the binding parameters of bouvardin 
to the eukaryotic ribosome. 
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